Ivacaftor, also known as VX-770, is a drug used to treat cystic fibrosis in people with certain mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, who account for 4–5% cases of cystic fibrosis, and is included in a combination drug, lumacaftor/ivacaftor, which is used to treat people with cystic fibrosis who have the F508del mutation in CFTR. Ivacaftor is a "potentiator" of CFTR, meaning it increases the probability that the defective channel will be open and allow chloride ions pass through the channel pore.
Zhang, Rui; Han, Guanyu; Jiang, Luobin; Shen, Yao; Yang, Rui; Mao, Yongjun; Wang, Hang. An Efficient Synthesis of Ivacaftor. Journal of Heterocyclic Chemistry. Volume 54. Issue 6. Pages 3169-3173. Journal; Online Computer File. (2017).
Hadida, Sabine; Van Goor, Fredrick; Zhou, Jinglan; Arumugam, Vijayalaksmi; McCartney, Jason; Hazlewood, Anna; Decker, Caroline; Negulescu, Paul; Grootenhuis, Peter D. J. Discovery of N-(2,4-Di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide (VX-770, Ivacaftor), a Potent and Orally Bioavailable CFTR Potentiator. Journal of Medicinal Chemistry. Volume 57. Issue 23. Pages 9776-9795. Journal; Online Computer File. (2014).
He, Yang; Xu, Qien; Ma, Wenpeng; Zhang, Jian; Sun, Hongbing; Shen, Jingshan. Expeditious synthesis of ivacaftor. Heterocycles. Volume 89. Issue 4. Pages 1035-1040. Journal. (2014).
Vasudevan, N.; Jachak, Gorakhnath R.; Reddy, D. Srinivasa. Breaking and Making of Rings: A Method for the Preparation of 4-Quinolone-3-carb-oxylic Acid Amides and the Expensive Drug Ivacaftor. European Journal of Organic Chemistry. Volume 2015. Issue 34. Pages 7433-7437. Journal; Online Computer File. (2015).
